Kidney Disease kills more people than breast cancer, leukemia or prostate cancer. One in 3 of your patients is at risk for CKD; do you know who they are? HTN is the most common comorbidity and most kidney patients die of CV disease. After decades of just wringing our hands, we have NEW GUIDELINES!!!, NEW MEDICATIONS!!! and we can actually slow progression of kidney disease. When was the last time you found out you could change outcomes for your patients?! Come to CKD in 2026 to learn how to identify and manage CKD in the 21st century!

Objectives: 1) Define stages of CKD using the new race-neutral eGFR calculator 2) Review urinary testing needed to both stage and predict progression of CKD 3) Discuss new KDIGO guidelines for management of CKD patients with a goal to slow disease progression

This is a lecture designed to help outpatient providers use the red light, yellow light green light method to decide where they need to go.

Objectives: 1. Review and discuss how some females do not get triaged appropriately and how this can delay care 2. Discuss how the EKG will help you triage where the patient will go next - green light (home), Yellow light to cardiology and Red light to the ER 3. Review cases of PE and acs

Primary care clinicians are increasingly responsible for initiating and managing basal insulin therapy in patients with type 2 diabetes (T2D), yet many remain unfamiliar with emerging once-weekly basal insulin options and their potential role in simplifying care. This CME activity equips PCPs, NPs, and PAs with the knowledge and confidence needed to incorporate these next-generation therapies into clinical practice. Through an evidence-based review, faculty will compare the mechanisms and pharmacokinetic/pharmacodynamic profiles of once-weekly versus once-daily basal insulins, interpret the latest efficacy and safety data, and explore how these agents may help overcome treatment inertia and improve adherence. Participants will learn practical strategies for developing individualized treatment plans, including best practices for initiation, dosing, and titration. Insights from recent learner feedback highlight a strong need for continued, hands-on education in insulin management, titration guidance, and patient follow-up—needs directly addressed by this program to support more effective and convenient diabetes care.

Objectives: 1. Compare the mechanisms and pharmacokinetic/pharmacodynamic properties of once-weekly and once-daily basal insulins to anticipate their potential clinical us. 2. Interpret the efficacy and safety data for emerging once-weekly basal insulins and apply this knowledge to anticipate their potential role in managing type 2 diabetes. 3. Develop individualized evidence-based treatment plans for patients with type 2 diabetes who require basal insulin that incorporates best practices for initiation, dosing, and titration.

Cardiometabolic Disease is a leading cause of morbidity and mortality in North Carolina and across the United States, with disproportionate burdens in rural communities and among certain racial and ethnic minority groups. While Hemoglobin A1c remains a central marker of glycemic control, it captures only one narrow dimension of cardiometabolic health. Despite therapeutic advances, many patients with diabetes continue to face elevated cardiovascular risk due to coexisting, undertreated risk factors and underuse of evidence?based screening tools and medications. Physician Associates are increasingly responsible for managing obesity, type 2 diabetes, chronic kidney disease (CKD), and cardiovascular disease within limited visit times and resource?variable settings. This session will equip participants with evidence?based, guideline?aligned strategies to assess and manage cardiometabolic risk factors and support early initiation of medications with proven cardiovascular and renal benefits used as first?line therapy when appropriate, independent of A1c levels. I will incorporate case?based learning to identify high?risk patients, apply validated risk calculators, and individualize treatment plans that prioritize long?term cardiovascular and renal outcomes. Emphasis will be placed on practical implementation, including EMR screening tools, medication selection, and side?effect management. The session will also address the role of social determinants of health in shaping cardiometabolic outcomes and highlight strategies to reduce inequities in care.

Objectives: 1. Identify cardiometabolic risk factors in people with prediabetes and type 2 diabetes and explain how each contributes to cardiovascular and renal risk. 2. Apply guideline based screening tools to stratify cardiometabolic risk and integrate results into shared decision making with patients. 3. Develop an individualized cardiometabolic risk-reduction treatment plan that integrates pharmacologic interventions and lifestyle recommendations, addressing weight management, blood pressure control, lipid control, and renal protection for patients with prediabetes and type 2 diabetes, independent of baseline A1c . 4. Compare GLP-1 receptor agonists, dual agonists, and SGLT2 inhibitors based on cardiovascular, renal and weight-related benefits. 5. Identify disparities in cardiometabolic disease burden among racial/ethnic subgroups, rural communities, and low?income populations, and implement social determinants of health informed strategies to reduce inequities in care.

Continuous Glucose Monitoring is crucial to the management of your patients with diabetes, and there are challenges with translating the resulting data into practical treatment decisions in primary care. This presentation will dive into those challenges, as well as considering what’s next in the world of CGM, and using CGM to ease the patient burden.

Objectives: 1. Apply accurate strategies for interpreting CGM data to inform diabetes treatment decisions and support integration of CGM into clinical practice 2. Integrate CGM into routine care of patients with diabetes in primary care settings who would benefit from CGM use 3. Describe new and emerging CGM technologies, such as OTC CGM devices and continuous ketone monitoring, including how they can be integrated into clinical practice 4. Collaborate with the multidisciplinary health care team for diabetes care and incorporation of CGM into diabetes management.